Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $250.60M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 1.14M
Average 1.12M
IPSC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Century Therapeutics, Inc.NASDAQ: IPSC
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.45M fell 40.4% year over year, ahead of the -50.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at -13.8% a year.
Context
- Stock-based compensation amounted to 6.3% of revenue in FY2025, down 186.3 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -40.4% holds above the trailing-twelve-month pace of -50.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.84M USD
- Year-over-year change
- -46.1%
- 4-year CAGR
- +10.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.84M | -46.1% |
| FY2024 | 2024-12-31 | 12.69M | -13.2% |
| FY2023 | 2023-12-31 | 14.62M | +37.1% |
| FY2022 | 2022-12-31 | 10.67M | +128.9% |
| FY2021 | 2021-12-31 | 4.66M | — |
Stock-Based Compensation vs competitors
How IPSC compares with its peers on the latest reported figures
- IPSC's LTM Mar 2026 stock-based compensation of $5.86M is the 3rd largest of the 8 companies compared; the peer median is $3.92M.
- Its year-over-year change of -50.8% is the 7th highest of 8, against a peer median of -22.6%.
- Over three fiscal years its annual growth of -13.8% compares with a peer median of -21.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $4.27B | +453006.6% | — | — |
| LTM Mar 2026 | $13.5M | -20.7% | -26.5% | 8.9% | |
| LTM Mar 2026 | $5.86M | -50.8% | -13.8% | — | |
| LTM Mar 2026 | $5.14M | -37.3% | +4.9% | 1543.3% | |
| LTM Mar 2026 | $3.92M | -52.4% | — | — | |
| LTM Mar 2026 | $3.45M | -44.6% | -20.7% | 10.6% | |
| LTM Mar 2026 | $2.63M | -22.6% | -21.7% | — | |
| LTM Mar 2026 | $1.82M | +13.4% | — | 128.8% | |
| Peer median (excluding IPSC) | $3.92M | -22.6% | -21.2% | 69.7% | |
Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Depreciation & Amortization | 3.75M | 8.44M | 13.04M | 13.3M | 13.1M |
| Deferred Income Tax | 0 | 0 | 0 | 870K | (73K) |
| Stock-Based Compensation | 4.66M | 10.67M | 14.62M | 12.69M | 6.84M |
| Change in Working Capital | (2.8M) | 123.95M | 9.38M | (9.28M) | (114.55M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.85M) | (4.79M) | (2.36M) | (1.47M) | 1.56M |
| Other Working Capital | (949K) | 128.73M | 11.74M | (7.81M) | (116.12M) |
| Other Non-Cash Items | 1.21M | 1.93M | 11.28M | (1.15M) | 389K |
| Operating Cash Flow | (89M) | 14.05M | (88.35M) | (110.14M) | (103.88M) |
| Capital Expenditures | (44.97M) | (30.6M) | (13.74M) | (154K) | (848K) |
| Acquisitions (Net) | 0 | (238.22M) | 0 | (9.61M) | 0 |
| Purchases of Investments | (330.03M) | (254M) | (209.03M) | (119.55M) | (51.17M) |
| Sales of Investments | 76.67M | 271.48M | 283.9M | 176.79M | (51.17M) |
| Other Investing Activities | 0 | 238.22M | 0 | 0 | 210.7M |
| Investing Cash Flow | (298.34M) | (13.13M) | 61.13M | 47.48M | 107.5M |
| Debt Repayment | 0 | 0 | (10.24M) | 0 | 0 |
| Common Stock Issued | 221.62M | 27.16M | 516K | 74.56M | 173K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 36.53M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 417.77M | 27.16M | (9.73M) | 74.56M | 173K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 30.43M | 28.08M | (36.94M) | 11.91M | 3.8M |
| Free Cash Flow | (133.97M) | (16.55M) | (102.08M) | (110.29M) | (104.72M) |
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.